Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients

Show simple item record Mondelo-Macía, Patricia Rodríguez-López, Carmela Valiña, Laura Aguín, Santiago León-Mateos, Luis García-González, Jorge Abalo, Alicia Rapado-González, Oscar Suárez-Cunqueiro, Mercedes Díaz-Lagares, Angel Curiel, Teresa Calabuig-Fariñas, Silvia Azkárate, Aitor Obrador-Hevia, Antònia Abdulkader, Ihab Muinelo-Romay, Laura Diaz-Peña, Roberto López-López, Rafael 2020-03-10T11:55:15Z 2020-03-10T11:55:15Z
dc.description.abstract [eng] MET alterations may provide a potential biomarker to evaluate patients who will benefit from treatment with MET inhibitors. Therefore, the purpose of the present study is to investigate the utility of a liquid biopsy-based strategy to assess MET alterations in cancer patients. We analyzed MET amplification in circulating free DNA (cfDNA) from 174 patients with cancer and 49 healthy controls and demonstrated the accuracy of the analysis to detect its alteration in patients. Importantly, a significant correlation between cfDNA concentration and MET copy number (CN) in cancer patients (r = 0.57, p <10−10) was determined. Furthermore, we evaluated two approaches to detect the presence of MET on circulating tumor cells (CTCs), using the CellSearch® and Parsortix systems and monitored patients under anti-EGFR treatment (n = 30) combining both cfDNA and CTCs analyses. This follow-up provides evidence for the potential of MET CN assessment when patients develop resistance to anti-EGFR therapy and a significant association between the presence of CTCs MET+ and the Overall Survival (OS) in head and neck cancer patients (P = 0.05; HR = 6.66). In conclusion, we develop specific and noninvasive assays to monitor MET status in cfDNA/CTCs and demonstrate the utility of plasma MET CN determination as a biomarker for monitoring the appearance of resistance to anti-EGFR therapy.
dc.format application/pdf
dc.relation.ispartof Cells, 2020, vol. 9, num. 2, p. 1-18
dc.rights , 2020
dc.subject.classification 576 - Biologia cel·lular i subcel·lular. Citologia
dc.subject.classification 616 - Patologia. Medicina clínica. Oncologia
dc.subject.other 576 - Cellular and subcellular biology. Cytology
dc.subject.other 616 - Pathology. Clinical medicine
dc.title Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients
dc.type info:eu-repo/semantics/article 2020-03-10T11:55:15Z
dc.rights.accessRights info:eu-repo/semantics/openAccess

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search Repository

Advanced Search


My Account